Skip to main content

HIV Studies

Collaborative Clinical Trials

AT1026: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

PACTG1026S-Pharmacokinetic Properties of Antiretroviral Drugs During Pregnancy

Diseases Treated:

HIV Infection


This is a non-therapeutic clinical trial that is only open to St. Jude patients.

  • The subject has been enrolled on IMPAACT P1025.
View Trial

GS1269: Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Regimen

A Phase 2/3, Open-Label Multi- Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a Tenofovir Disoproxil Fumarate (TDF)-Containing Regimen, Initial Version, June 23, 2014

Diseases Treated:



  • Participant is HIV-1 infected male or female aged six (6) to less than eight-teen (18) years of age at Baseline.
  • Participant is currently on a stable 2-NRTI (TDF containing) regimen that includes a protocol specified 3rd ARV agent for greater than or equal to six (6) consecutive months prior to screening.
  • Participant does not have an acquired immunodeficiency syndrome (AIDS) indicator condition with onset within thirty (30) days prior to screening.
View Trial

IMPAACT2002: Behavioral Therapy and Medication for Depression among Youth with HIV

Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression among Youth Living with HIV in the U.S.

Diseases Treated:



  • 12 to 24 years old
  • Receiving mental health or HIV-related care at participating IMPAACT site
  • HIV-positive
  • Diagnosis of nonpsychotic depression
  • Current depressive symptoms that warrant intervention
  • Reads and speaks English
View Trial

P1093: Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents

Diseases Treated:

Human Immunodeficiency Virus


  • At least 4 weeks old but younger than 18 years old
  • Confirmed HIV-1 infection
  • Current or past treatment with HIV medications (Children younger than 2 years old may be eligible even if they have not been treated with HIV medications.)
View Trial